Prime editing system offers wide range of versatility in human cells, correcting disease-causing genetic variations
A team from the Broad Institute of MIT and Harvard has developed a new CRISPR genome-editing approach that has the potential to correct up to 89 percent of known disease-causing genetic variations.
Researchers have combined two of the most important proteins in molecular biology — CRISPR-Cas9 and a reverse transcriptase — into a single machine. The system, called prime editing, is capable of directly editing human cells in a precise, efficient, and highly versatile fashion.
“A major aspiration in the molecular life sciences is the ability to precisely make any change to the genome in any location. We think prime editing brings us closer to that goal,” said David Liu, core institute member, Richard Merkin Professor, vice chair of the faculty, and director of the Merkin Institute of Transformative Technologies in Healthcare at the Broad Institute of MIT and Harvard. “We’re not aware of another editing technology in mammalian cells that offers this level of versatility and precision with so few byproducts.”
Liu is the senior author of a paper published today in Nature that describes prime editing. The research was also led by first author Andrew Anzalone, a Jane Coffin Childs postdoctoral fellow in Liu’s lab at the Broad Institute.
A new CRISPR approach
Prime editing differs from previous genome-editing systems in that it uses RNA to direct the insertion of new DNA sequences in human cells.
The first CRISPR tool harnessed for genome editing in human cells, pioneered at the Broad Institute, MIT, and Harvard, was the Cas9 protein. Cas9 makes nearby breaks on each DNA strand, cutting the DNA entirely. These tools can disrupt target genes at a specific location and then make it possible to add new sequences through recombination of new DNA into the site, directed by the cell itself.
Base editing, first developed by Liu’s laboratory, builds on this technology, fusing Cas9 to proteins that can perform chemical reactions to change a single letter of DNA into another. Current base editors can make four types of single-base changes efficiently: C to T, T to C, A to G, and G to A.
The new prime editing system involves coupling Cas9 to a different protein called reverse transcriptase. The molecular complex uses one strand of the target DNA site to “prime,” or initiate, the direct writing of edited genetic information into the genome.
A new type of engineered guide RNA, called a pegRNA, directs the prime editor to its target site, where a modified Cas9 cuts one strand of the DNA. The pegRNA also contains additional RNA nucleotides encoding the new edited sequence. To transfer this information, the reverse transcriptase element reads the RNA extension and writes the corresponding DNA nucleotides into the target spot.
Edits made to order
In the Nature paper, the team demonstrated prime editing’s ability to precisely correct gene variants that cause sickle-cell anemia, requiring the conversion of a specific T to an A, and Tay-Sachs disease, requiring the removal of four DNA letters at a precise location in the genome.
The researchers further report a variety of successful edit types in human cells and primary mouse neurons, including all 12 possible ways to replace one DNA letter with another, insertions of new DNA segments up to 44 DNA letters long, precise deletions of up to 80 DNA letters, and modifications combining these different types of edits.
“With prime editing, we can now directly correct the sickle-cell anemia mutation back to the normal sequence and remove the four extra DNA bases that cause Tay-Sachs disease, without cutting DNA entirely or needing DNA templates,” said Liu, who is also a professor of chemistry and chemical biology at Harvard University and a Howard Hughes Medical Institute investigator. “The beauty of this system is that there are few restrictions on the edited sequence. Since the added nucleotides are specified by the pegRNA, they can be sequences that differ from the original strand by only one letter, that have additional or fewer letters, or that are various combinations of these changes.”
“The versatility of prime editing quickly became apparent as we developed this technology,” said Anzalone. “The fact that we could directly copy new genetic information into a target site was a revelation. We were really excited.”
The researchers report that prime editing achieves successful edits with a lower rate of undesired “off-target” changes compared with approaches that require making nearby breaks on each DNA strand. Prime editing can also make precise single-nucleotide changes in target sequences that base editors have difficulty accessing, according to the team’s data.
Liu’s team intends to continue optimizing prime editing, including by maximizing its efficiency in many different cell types, further investigating potential effects of prime editing on cells, additional testing in cell and animal models of disease, and exploring delivery mechanisms in animals to provide a potential path for human therapeutic applications.
The researchers and the Broad Institute are making this technology freely available to the academic and nonprofit communities, including by sharing vectors through the nonprofit Addgene. For these groups, no license is necessary.
The Broad Institute is making prime editing tools available to license nonexclusively for research and manufacturing by companies, and for the commercial development of tools and reagents. For human therapeutic use, the Broad Institute has licensed the technology to Prime Medicine under the inclusive innovation model. As has been publicly reported, Beam Therapeutics has received a sublicense from Prime Medicine for the use of prime editing in certain fields and for certain applications. (Liu is a consultant and co-founder of both Prime Medicine and Beam Therapeutics.)
Learn more: Genome editing with precision
The Latest on: Prime editing
[google_news title=”” keyword=”prime editing” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Prime editing
- Prime Medicine to Begin Clinically Testing Genetic Therapy in Chronic Granulomatous Diseaseon April 30, 2024 at 2:11 pm
The firm's gene-editing therapy PM359 is designed to correct a specific variant in the NCF1 gene, which can cause the rare disorder.
- Prime Medicine Gets FDA Okay for First Trial of Gene Editing Techniqueon April 30, 2024 at 8:27 am
The FDA has cleared a clinical trial of an ex vivo prime editing candidate in patients with a rare disease, Prime Medicine announced Monday. The technique taps CRISPR technology to rewrite defective ...
- Prime Medicine gets green light for trials of first-ever prime editing drugon April 30, 2024 at 3:01 am
Prime Medicine has been granted approval by the US Food and Drug Association (FDA) to initiate trials of the first-ever prime editing drug. The FDA cleared Prime Medicine’s investigational new drug ...
- Prime editing comes of age as FDA clears human trialson April 30, 2024 at 12:46 am
Prime editing aims to improve on the CRISPR/Cas9 gene-editing approach by allowing changes to be made to DNA without breaking the double helix or using donor DNA. It is more broadly applicable than ...
- FDA Clears Prime Medicine’s IND for First Prime Editing Therapyon April 29, 2024 at 5:00 pm
Prime Medicine said it has gained FDA clearance for the first human trials of a prime editing therapy as the agency has approved an investigational new drug (IND) application for the company’s first ...
- Prime Medicine receives FDA clearance to run first prime editing clinical trialon April 29, 2024 at 8:29 am
The FDA has OK'd the first-ever human trial of prime editing, Prime Medicine announced Monday, opening the door for testing a new technology that backers hope will widen the array of diseases that can ...
- Prime gets FDA green light to begin first trial test of ‘prime editing’on April 29, 2024 at 4:35 am
The company will soon start a Phase 1/2 study of its treatment for chronic granulomatous disease, a milestone for the search-and-replace gene editing technology.
- Buy Rating Affirmed for Prime Medicine, Inc. on Strong Preclinical Data and Promising Clinical Outlookon April 25, 2024 at 9:35 am
Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on Prime Medicine, Inc. (PRME – Research Report). The associated ...
- Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetingson April 23, 2024 at 7:01 am
Presentations include new preclinical data for PM359, further demonstrating ability of Prime Editors to efficiently, reproducibly and durably ...
- Probing the Inner World of Cells Provides Unexpected Boost to Prime Editingon April 23, 2024 at 4:02 am
While probing the inner workings of cells, Dr. Britt Adamson, assistant professor of molecular biology at Princeton University, and colleagues discovered a way to boost the efficiency of prime editing ...
via Bing News